Osteologix A/s

Forward Pharma A/s

Aditech Pharma Ag

Henrik Nilsson

Stephan Christgau

Joseph R Robinson

Christian Hansen

Jens E T Andersen

Henry G Bone, Iii

Jens Et Andersen

Bernd W Müller

Henry G Iii Bone

Jens ET Andersen

Florian Schönharting

A combination treatment, wherein a strontium-containing compound together with one or more active substances capable of reducing the incidence of bone fracture and/or increasing bone density and/or improving healing of fractured bone and/or improving bone quality are administered for use in the treatment and/or prophylaxis of cartilage and/or bone conditions.

Combination treatment with strontium for the prophylaxis and/or treatment of cartilage and/or bone conditions

A method for the treatment and/or prophylaxis of an osteonecrotic bone disease in a mammal in need thereof, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis, Legg-Calve-Perthes disease and femoral head necrosis, the method comprising administering an effective dose of a strontium-containing compound (a) to the mammal. A method for the treatment and/or prophylaxis of an osteonecrotic bone disease, such as, e.g., idiopathic or secondary osteonecrosis, avascular bone necrosis, glucocorticoid induced bone ischemia/osteonecrosis and femoral head necrosis, in a mammal who is to be or is treated with a therapeutic agent (b) known to or suspected of inducing apoptosis and/or necrosis of bone cells, the method comprising administering a strontium-containing compound (a) in combination with (b).

Strontium-containing compounds for use in the prevention or treatment of necrotic bone conditions

Compounds and pharmaceutical compositions for use in the treatment and/or prophylaxis of cartilage and/or bone conditions and for methods of treating such condition. The compounds are salts of strontium that have a water-solubility of from about 1 g/l to about 100 g/l at room temperature, especially amino acid salts of strontium or dicarboxylic acid salts of strontium. Examples of novel water-soluble strontium salts are e.g. strontium glutamate and strontium alpha-ketoglutarate. The present invention also relates to an improved method for preparing the strontium salt of glutamic acid.

Water-soluble strontium salts for use in treatment of cartilage and/or bone conditions

Growing community of inventors

Copenhagen, Denmark

Henrik Nilsson